DermTech Past Earnings Performance
Past criteria checks 0/6
DermTech's earnings have been declining at an average annual rate of -41.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 35.5% per year.
Key information
-41.5%
Earnings growth rate
-7.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 35.5% |
Return on equity | -176.5% |
Net Margin | -659.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics
Sep 15We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth
Sep 03DermTech: Transforming The Melanoma Diagnosis Landscape
Aug 31DermTech: Becoming More Appealing, Despite Nosebleed Valuation
Aug 09DermTech appoints former Myriad Genetics executive as new chief medical officer
Jun 16We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 05DermTech initiated buy at BTIG on the potential of PLA test
May 03DermTech rises 18% on report Cigna covering early melanoma detection test
Apr 27Revenue & Expenses BreakdownBeta
How DermTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 15 | -101 | 83 | 15 |
30 Sep 23 | 14 | -110 | 90 | 17 |
30 Jun 23 | 14 | -120 | 97 | 19 |
31 Mar 23 | 14 | -118 | 98 | 22 |
31 Dec 22 | 15 | -117 | 95 | 24 |
30 Sep 22 | 15 | -115 | 92 | 25 |
30 Jun 22 | 14 | -106 | 84 | 24 |
31 Mar 22 | 13 | -93 | 75 | 20 |
31 Dec 21 | 12 | -78 | 62 | 16 |
30 Sep 21 | 11 | -63 | 50 | 12 |
30 Jun 21 | 9 | -52 | 41 | 9 |
31 Mar 21 | 7 | -45 | 35 | 7 |
31 Dec 20 | 6 | -36 | 30 | 5 |
30 Sep 20 | 5 | -31 | 27 | 4 |
30 Jun 20 | 5 | -27 | 24 | 3 |
31 Mar 20 | 4 | -21 | 19 | 3 |
31 Dec 19 | 3 | -20 | 15 | 2 |
30 Sep 19 | 2 | -18 | 12 | 2 |
30 Jun 19 | 2 | -14 | 8 | 2 |
31 Mar 19 | 3 | -13 | 7 | 2 |
31 Dec 18 | 2 | -10 | 6 | 2 |
31 Dec 17 | 2 | -8 | 6 | 2 |
30 Jun 14 | 0 | -6 | 2 | 3 |
31 Mar 14 | 0 | -6 | 2 | 2 |
Quality Earnings: DMTK is currently unprofitable.
Growing Profit Margin: DMTK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DMTK is unprofitable, and losses have increased over the past 5 years at a rate of 41.5% per year.
Accelerating Growth: Unable to compare DMTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DMTK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: DMTK has a negative Return on Equity (-176.45%), as it is currently unprofitable.